India’s Serum says produced 40 million doses of AstraZeneca Covid-19 vaccine
Reuters |
Reuters | Posted by Mallika Soni Nov 12, 2020 12:46 PM IST
At present, SII is conducting Phase 2/3 clinical trial of Covishield at 15 different centres across the country.
Serum Institute of India, the world’s largest vaccine producer, said on Thursday it has made 40 million doses of AstraZeneca’s potential Covid-19 vaccine, and would soon begin making Novavax’s rival shot, as they both seek regulatory approval.
Serum said it has enrolled 1,600 participants in India for late-stage trials of AstraZeneca’s candidate, and also plans to seek regulatory approval to run late-stage trials for the Novavax vaccine.
HT launches Crick-it, a one stop destination to catch Cricket, anytime, anywhere. Explore now!
Read more | Serum Institute completes phase 3 trial recruitment for Oxford-AstraZeneca Covid-19 vaccine
The AstraZeneca vaccine, co-developed by Oxford University, is the most advanced in human testing in India, Serum said.
Discover the complete story of India's general elections on our exclusive Elections Product! Access all the content absolutely free on the HT App. Download now!
Get Current Updates on India News, Lok Sabha Election 2024 live, Infosys Q4 Results Live, Elections 2024, Election 2024 Date along with Latest News and Top Headlines from India and around the world.
Get Current Updates on India News, Lok Sabha Election 2024 live, Infosys Q4 Results Live, Elections 2024, Election 2024 Date along with Latest News and Top Headlines from India and around the world.
Share this article